ClinicalTrials.gg

Program

trenibotulinumtoxinE

Also written as “AGN-151586” and “TrenibotulinumtoxinE and OnabotulinumtoxinA”.

Its studies are led by AbbVie.

Furthest: phase 3, since Feb 14, 202211 company-led studies, 3 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie113 open or runningphase 3since Feb 14, 2022Sep 4, 2019Feb 2027phase 1 · NCT07756580

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 4, 2019First study: phase 2 study in Glabellar LinesFirst studyNCT04096326 · 198 enrolled · United States
  2. Feb 14, 20223 phase 3 studies in Glabellar LinesNCT05248893, NCT05248880, NCT05248867
  3. Aug 9, 2022Phase 1 study in Glabellar LinesNCT05496335 · 90 enrolled · United States
  4. Nov 22, 2023Phase 1 study in Moderate to Severe Glabellar LinesNCT06151561 · 24 enrolled · Japan
  5. Mar 7, 2024Phase 3 study in Glabellar LinesNCT06308198 · 161 enrolled · China, Japan, Taiwan
  6. Feb 14, 2025Phase 1 study in Glabellar LinesNCT06834789 · 132 enrolled · United States
  7. Jul 23, 2026Phase 2 study in Forehead LinesNCT07730554 · 84 enrolled · United States
  8. Aug 7, 2026Phase 1 study in Glabellar LinesNCT07756580 · 143 enrolled · United States
  9. Oct 7, 2026Phase 2 study in Upper Facial LinesNCT07871513 · 300 planned · United States

Ahead

  1. Feb 2027Primary completion: phase 1 study in Glabellar LinesNCT07756580
  2. Jun 2028Primary completion: phase 2 study in Upper Facial LinesNCT07871513

TargetBeta

SNAP25 →read by rule
“Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme”ChEMBL 37, by rule

Other programs on SNAP25

ProgramCompanyFurthest phaseStudies
botulinum toxin type AAbbViephase 4286
prabotulinumtoxin Aruleaeon-biopharma-incphase 39

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07871513Upper Facial Lines · United States2RecruitingJun 2028300
NCT07756580Glabellar Lines · United States1Active, not recruitingFeb 2027143
NCT07730554Forehead Lines · United States2Active, not recruitingOct 202684
NCT06834789Glabellar Lines · United States1CompletedNov 3, 2025132
NCT06308198Glabellar Lines · China, Japan, Taiwan3CompletedFeb 26, 2025161
NCT06151561Moderate to Severe Glabellar Lines · Japan1CompletedApr 3, 202424
NCT05496335Glabellar Lines · United States1CompletedMay 30, 202390
NCT05248893Glabellar Lines · United States, Puerto Rico3CompletedJun 26, 2023992
NCT05248880Glabellar Lines · United States, Canada3CompletedFeb 1, 2023309
NCT05248867Glabellar Lines · United States, Canada, Germany and more3CompletedMar 17, 2023638
NCT04096326Glabellar Lines · United States2CompletedSep 9, 2020198

How it is read

Names in the registry

  • “AGN-151586”, 10 entries
  • “TrenibotulinumtoxinE and OnabotulinumtoxinA”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.